Summary
This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.
Official Title
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-4021586 in Adults With Symptomatic Heart Failure With Preserved Ejection Fraction
Keywords
Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF), Symptomatic heart failure with preserved ejection fraction, HFpEF, Heart failure, CK-4021586, CK-586, AMBER-HFpEF, AMBER, Cardiac myosin inhibitor, CMI, CY 9021, CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)